Cargando…
Pulmonary Edema in COVID-19 Treated with Furosemide and Negative Fluid Balance (NEGBAL): A Different and Promising Approach
In COVID-19, pulmonary edema has been attributed to “cytokine storm”. However, it is known that SARS-CoV2 promotes angiotensin-converting enzyme 2 deficit, increases angiotensin II, and this triggers volume overload. Our report is based on COVID-19 patients with tomographic evidence of pulmonary ede...
Autores principales: | Santos, Jose L. Francisco, Zanardi, Patricio, Alo, Veronica, Rodriguez, Marcelo, Magdaleno, Federico, De Langhe, Virginia, Dos Santos, Vanina, Murialdo, Giuliana, Villoldo, Andrea, Coria, Micaela, Quiros, Diego, Milicchio, Claudio, Garcia Saiz, Eduardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658626/ https://www.ncbi.nlm.nih.gov/pubmed/34884300 http://dx.doi.org/10.3390/jcm10235599 |
Ejemplares similares
-
Lung Injury in COVID-19 Has Pulmonary Edema as an Important Component and Treatment with Furosemide and Negative Fluid Balance (NEGBAL) Decreases Mortality
por: Santos, Jose L. Francisco, et al.
Publicado: (2023) -
Intravenous furosemide vs nebulized furosemide in patients with pulmonary edema: A randomized controlled trial
por: Barzegari, Hasan, et al.
Publicado: (2021) -
Resolution of Macular Edema after Systemic Treatment with Furosemide
por: Koo, Nam Kyun, et al.
Publicado: (2012) -
Therapy with the Combination of Tolvaptan and Furosemide for Refractory Edema in Nephrotic Syndrome
por: Meena, Jitendra, et al.
Publicado: (2020) -
Temporal bone histopathology of furosemide ototoxicity
por: Santos, Felipe, et al.
Publicado: (2017)